Plain-English translation of NCT05878769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people with chronic obstructive pulmonary disease (COPD) who already completed an initial 52-week trial of . Researchers want to learn more about the long-term safety and effectiveness of this medication when people continue taking it for an extended period. You would receive the medication as an injection every two weeks for as long as the study continues.
While earlier trials showed may help people with COPD, doctors need to understand how safe and effective it remains when people use it over months or years. This study gathers that important long-term information.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will continue receiving injections of the medication under your skin every two weeks throughout the study period. You will need to attend regular study visits so doctors can monitor your health, watch for any side effects, and measure how well the medication is working for your COPD symptoms. The study continues until the sponsor decides it has collected enough safety and effectiveness information.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States